In a news release dated March 26, 2019, the United States Food and Drug Administration (FDA) announced the approval of Mayzent® (siponimod) oral tablets to treat adults with relapsing forms of multiple sclerosis (MS). The approval includes individuals with clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS). Mayzent is the only disease-modifying therapy (DMT) to be approved in recent years for active secondary-progressive MS. To read this article in its entirety Click the link https://mymsaa.org/news/mayzent-fda-approved/
Recent Posts
- Lynchburg Support Group Has Exciting News
- Your Questions Answered About the New Roanoke Area MS Center and Blue Ridge Neurology
- Join Us to Meet New MS Center Leadership
- From the MS Community of Southwest Virginia: Gratitude for Dr. Jill Cramer
- MS and Memory: The Other Me Must Have Lost it
- When You’re Hot, You’re Hot
- When MS Says No, But You Say Yes
- Bluefield/Princeton, WV
- Bristol, VA
- Lynchburg, VA